Odyssey Therapeutics, Inc. (ODTX)
NASDAQ: ODTX · Real-Time Price · USD
17.33
-0.94 (-5.12%)
Oct 13, 2026, 3:05 PM EDT - Market open
Odyssey Therapeutics Revenue
Odyssey Therapeutics had revenue of $99.00K in the twelve months ending June 30, 2026, down -96.70% year-over-year. In the year 2025, Odyssey Therapeutics had annual revenue of $2.98M, down -33.45%. That makes Odyssey Therapeutics the 46,053rd largest company in the world by revenue and 6,797th in the United States.
Revenue (ttm)
$99.00K
Revenue Growth
-96.70%
P/S Ratio
8,627.74
Revenue / Employee
$990
Employees
100
Market Cap
830.19M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | -1.50M | -33.45% |
| Dec 31, 2024 | 4.47M | 3.44M | 331.24% |
| Dec 31, 2023 | 1.04M | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
ODTX News
- 1 day ago - Odyssey Therapeutics initiated with a Buy at UBS - TheFly
- 4 days ago - Odyssey Therapeutics initiated with an Outperform at Raymond James - TheFly
- 7 days ago - Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 - GlobeNewsWire
- 20 days ago - Odyssey Therapeutics Transcript: Stifel 2026 Virtual Immunology and Inflammation Forum - Transcripts
- 27 days ago - Odyssey Therapeutics to Participate in Stifel 2026 Virtual Immunology and Inflammation Forum - GlobeNewsWire
- 4 weeks ago - Odyssey Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - H.C. Wainwright has increased confidence in Odyssey after Beeline data - TheFly
- 6 weeks ago - Odyssey Therapeutics initiated with a Buy at H.C. Wainwright - TheFly